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S10 2. Screening & Diagnosis
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Background: Since June 1996 we perform a newborn screening for cystic ﬁbrosis
in administrative District of Dresden in saxony. Until 31th of December 2007 we
did a two step IRT/DNA-Screening. Since 1st of January 2008 we do a two step
IRT/PAP-screening.
Methods: IRT is measured in the dried blood spots taken from newborns between
the 36th and 72th hour of live together with routine newborn screening. In case
of a result over the 99. Percentile until December 2007 we searched for the three
cftr-mutations DF508, G551D and R553X. Children were seen for sweattesting if
we found at least one Mutation. Since January 2008 we select children for sweat
testinjg if we have an IRT over the 99. Percentile and a PAP >1.0 ng/ml or an IRT
>the 97.5. Percentile and a PAP >1.8 ng/ml. All patients with an IRT elevated over
150 ng/ml are send for sweat testing.
Results: We screened 206 669 children, 160675 by IRT/DNA-, 45994 by IRT/PAP-
screening for cystic ﬁbrosis. In 45 patiens we conﬁrmed the diagnose of cystic
ﬁbrosis by sweat testing ang further genetic diagnostic. So the Incidence for cystic
ﬁbrosis in our population is 1: 4593. In four cases screened by IRT/DNA-Screening
the screening was false negativ. In three of this cases methodic errors were the cause.
The recall rate for sweat testing is higher for the IRT/PAP-Screening (0.18%) than
for the IRT/DNA-screening (0.09%) done only with 3 mutations.
Conclusion: Both methods show good sensitivity and speciﬁcy for detecting cystic
ﬁbrosis by newborn screening until now. IRT/PAP-screening could be an alternative
method to avoid genetical testing. Further Monitoring and higher numbers of
screened babies are needed.
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Objectives: To determine how early diagnosis of cystic ﬁbrosis, using neonatal
screening, affects clinical outcome.
Methods: Twenty children with cystic ﬁbrosis born before neonatal screening (NS)
was introduced (1994 to mid 2006), and a further nineteen children born during the
ﬁrst three years of the NS program (mid 2006 to 2007), were followed up to the age
of 3 year. The cohorts were compared on measures of clinical outcomes including
age of CF manifestation, physical status (height, weight, BMI %), microbiological
status, chest x-ray picture (Crispin-Norman score) and Shwachman score.
Conclusion: Analysis of all 39 patients at age 3 year conﬁrms signiﬁcant differences
between the groups, favoring the screened cohort for weight, BMI (p< 0.05),
chest x-ray scores (6.067±1.137 and 11.45±1.064, p = 0.049) and Shwachman
score (p = 0.001). But, there was no statistically signiﬁcant difference of the
anthropometric indices between the groups at any year (p> 0.05). The frequency
of Pseudomonas aeruginosa growth, in non-screened cohort was higher compared
to the screened group (75% and 37%; c2 = 5.77; df = 1; p = 0.016). Moreover only
in the non-screened group in sputum Stenotrophomonas maltophilia (20%) and
Brurkholderia cepacia (5%) were found. The combined Shwachman score was
an average 10.5 points higher in the screened group by 3 years of age (mean
Shwachman score 78).
Our observational study indicates that early treatment made possible by neonatal
screening may be important in determining subsequent clinical outcomes for
children with cystic ﬁbrosis.
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Background: UK Newborn CF Screening is unique, incorporating a second IRT
test (IRT-2) at 3−4 weeks for infants with one CF mutation, to reduce the number
of referrals for sweat tests. Clear information for families of infants with a low
IRT-2 (presumptive carriers) is vital. In our region, a Screening Link Health Visitor
(SLHV) visits families and provides a national leaﬂet stating: 1. Whilst a diagnosis
of CF can’t be excluded, this is unlikely 2. Their child is a carrier of a CF mutation
and carriers are healthy 3. CF is a risk for future pregnancies and 4. They or family
members may want to seek genetic counselling. We assessed the implementation
and outcomes of this system.
Methods: A survey on the process and subsequent family health choices was
completed prospectively by the SLHV 2 weeks after visiting and by the family
physician (GP) at 6 months.
Results: Around 29,000 infants/year were screened. 21 presumptive carriers were
identiﬁed in 3 years (less than half the anticipated number). Two were seen
inappropriately by CF specialists early on. The SLHV visited all other families
and in 18/19 the leaﬂet was discussed and left (discussion via an interpreter in
1/19). After initial contact, 1/19 families expressed concern about a sibling’s health.
No other concerns were raised. 11/19 GPs approached at 6 months completed the
survey. No infants had been seen for CF related health issues. 3/11 families had
discussed genetic advice and 2/11 were subsequently referred.
Conclusion: This system of family counselling for CF carriers is feasible. Follow-
up data suggest that most families are not seeking further health/genetic advice
reﬂecting low anxiety after the visit.
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Diagnostic criteria for inclusion in a CF registry can vary, which may introduce bias
in longitudinal analysis or (international) benchmarking. We explored whether patients
included in the Belgian CF registry fulﬁll stringent diagnostic criteria.
1087 patients (979 non-transplanted) made up the 2008 Belgian CF registry dataset.
Patients with sweat chloride >60mEq/l or 2 CFTR mutations identiﬁed were considered
as fulﬁlling CF diagnostic criteria. CFTR mutations were classiﬁed according to the
mutation databases CFTR1 and CFTR2 and expert advice (HC).
CF diagnostic criteria were not fulﬁlled in 64 subjects (5.9%), 55 of whom had a sweat
chloride between 30 and 60mEq/L. FEV1 does not worsen in increasing age categories
in the group 30−60mEq/L and 0/1 CFTR mutation.
Diagnostic characteristics
Sweat Chloride (mEq/l) >60 30−60 <30 Not reported Total
N (%) 795 (73.1) 87 (8.0) 15 (1.4) 190 (17.5) 1087
2 CFTR mutations 710 42 7 179 938
1 CFTR mutation 67 21 6 7 101
0 CFTR mutation 18 24 2 4 48
F508del homozygote (%) 388 (48.8) 3 (3.4) 1 (6.6) 110 (57.9) 502 (46.2)
1 class 4/5 mutation (%) 30 (3.8) 34 (39.1) 5 (33.3) 8 (4.2) 77 (7.1)
1 mutation of unknown relevance (%) 95 (11.9) 10 (11.5) 2 (13.3) 10 (5.3) 117 (10.8)
Pancreatic sufﬁciency (%) 78 (9.8) 55 (63.2) 7 (46.6) 8 (4.2) 148 (13.6)
The Belgian CF registry contains 5.9% subjects in whom the diagnosis of CF is not
clearcut. Lack of lung disease progression with age in this group strengthens the need
for more evidence of a CF diagnosis (clinical data, missing values, extensive gene
analysis). The signiﬁcance of several CFTR mutations is in doubt which further hampers
correct attribution of a CF diagnosis. A common and strict case deﬁnition of who is
analyzed in CF registries is needed.
